logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Carcinoma Breast Stage Iv

    FiltersReset Filters
    5 results

    • halaven

      (eribulin mesylate)
      Eisai Inc.
      Usage: HALAVEN is indicated for treating metastatic breast cancer in patients who have received at least two prior chemotherapy regimens, including anthracyclines and taxanes, and for unresectable or metastatic liposarcoma in patients previously treated with an anthracycline-containing regimen.

    • ixempra

      (ixabepilone)
      R-Pharm US Operating, LLC
      Usage: IXEMPRA is indicated for treating patients with metastatic or locally advanced breast cancer that is resistant to anthracyclines and taxanes, or when further anthracycline therapy is contraindicated. It can be used in combination with capecitabine or as a single agent when tumors are resistant to multiple treatments.

    • letrozole

      (Letrozole Tablets)
      Yiling Pharmaceutical, Inc.
      Usage: Letrozole is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for extended adjuvant therapy following tamoxifen. It is also used as a first and second-line treatment for advanced, locally advanced, or metastatic breast cancer in postmenopausal women.

    • tamoxifen citrate

      (Tamoxifen Citrate)
      Actavis Pharma, Inc.
      Usage: Tamoxifen citrate tablets are indicated for metastatic breast cancer, adjuvant treatment in node-positive and node-negative cases, ductal carcinoma in situ (DCIS) post-surgery, and reducing breast cancer incidence in high-risk women. Efficacy is higher in patients with estrogen receptor-positive tumors. Individual benefit-risk assessment is essential.

    • verzenio

      (abemaciclib)
      Eli Lilly and Company
      Usage: VERZENIO (abemaciclib) is indicated for adults with HR-positive, HER2-negative breast cancer. It is used in combination with endocrine therapy for early breast cancer at high risk of recurrence and for advanced or metastatic cases, either with an aromatase inhibitor, fulvestrant, or as monotherapy after prior treatments.